Expanded distribution of EmboCept® S DSM 50 µm in the Nordics

Magle Chemoswed is pleased to announce that PharmaCept GmbH has today confirmed the expanded distribution of the medical device EmboCept® S DSM 50 µm based on the Magle Chemoswed technology platform into the Nordic region. With this market expansion EmboCept® S DSM 50 µm is now available to hospitals in the Nordics. 
"Our partnership with PharmaCept has gone from strength to strength following the earlier grant of the CE Mark for EmboCept® S DSM 50 µm, this latest market expansion is an important milestones for the product and the future expansion and sales," said Justin Pierce, CEO of Magle Chemoswed. "PharmaCept is an important and strategic partner and we are thrilled to be able to support their efforts in expanding their reach and sales markets”.
EmboCept® S DSM 50 µm is a medical device based on the technology platform of Magle Chemoswed and is CE certified for chemoembolization of inoperable liver and lung tumors (DSM-TACE). The product is manufactured and supplied exclusively to PharmaCept by Magle Chemoswed and marketed by PharmaCept under their tradename of EmboCept® S.